Benitec Biopharma (ASX:BLT) has entered into an agreement with Maryland-based Omnia Biologics to manufacture material for its current first-in-man clinical trial for its TT-034 hepatitis C treatment.
This ensures the company has enough clinical material to complete the current trial.
The company is also moving to establish its own scalable manufacturing process in collaboration with third parties to supply large markets it is targeting.
Ann: MANUFACTURING UPDATE, page-31
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)